Taking people in NetherlandsPhase 1
First study of KLR-003 in healthy people and people with psoriasis
Tests the safety of KLR-003 in healthy adults and adults with psoriasis.
Key facts
- Who runs it
- Klear Bio Inc.
- Where
- Leiden, NetherlandsSee the site
- Trial code
- Registry title
- A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 182 people, planned
- Started
- 7 May 2026
- Expected to end
- 1 May 2029
- Type of study
- Interventional
- Record updated
- 23 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy adults and adults with psoriasis or another immune-mediated disease. It is a first study of KLR-003 in people.
- Age
- 18 to 64 years
- Sex
- Men and women can join.
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 64 years old?
Where in Netherlands
- Centre for Human Drug ResearchLeiden, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Plain-language title
- First study of KLR-003 in healthy people and people with psoriasisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Fit questions
- Built from 2026-525575-22-00, who can take part
- Record updated
- 23 October 2026